Asuragen’s molecular assays are designed to provide streamlined workflow and ease of use and is comprised of two product portfolios; Genetics and Oncology. The genetics portfolio includes assays aiding in the detection of the FMR1 and C9orf72 gene, while the Oncology assays use molecular methods ranging from qPCR to NGS to assist our understanding of cancer.
Biocartis provides fully integrated and broadly applicable molecular diagnostics. The Idylla is Biocartis’ fully automated, real-time PCR-based molecular diagnostics system which provides fast access to highly reliable clinical molecular diagnostic information. The Idylla can detect BRAF V600E, E2, D, K, R and M mutations within 90 minutes.
Devyser are specialists when it comes to complex DNA testing within hereditary diseases and oncology with products used to guide targeted cancer therapies and enable rapid prenatal diagnostics. Included in their portfolio is the BRCA NGS kit for detection of BRCA1 and BRCA2 in germline and somatic samples as well as the Fetal RHD kit used to determine fetal RHD status from maternal plasma.
SeptiCyte® RAPID revolutionizes sepsis diagnosis and treatment, with actionable results available in an hour. SeptiCyte®RAPID can determine the likelihood of sepsis and differentiate from non-infectious systemic inflammatory response syndrome (SIRS) in critically ill patients. The test, which uses a small volume of blood, can be performed easily in any hospital lab with the Biocartis Idylla™ molecular testing system. SeptiCyte®RAPID is available for IVD use in New Zealand and RUO in Australia.
T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.